-The Times of India MUMBAI: India's middle class has seen new entrants. Pani puri vendors, Dosa sellers, carpenters, welders, launderers, drivers and cable TV technicians have all pulled themselves out of the clutches of poverty and leapt into a section of the middle class — the bedrock of the economy. A paper titled 'The Rise of the New Middle Class and the Role of Offshoring of Services', co-authored by the head of...

-The Times of India NEW DELHI: In a significant move ensuring safety and efficacy of medicines, the health ministry has banned around 350 fixed dose combination (FDC) drugs that were widely available in the market till now. These medicines include FDCs based on codine, used in popular cough syrups like Phensedyl and Corex. The government has decided to prohibit manufacturing and sale of these medicines because they were found to be "irrational"...

-TheHansIndia.com Anantapur: The Telugu Desam government’s pet subsidised rice scheme conceived by the party’s founder N T Rama Rao has helped the party ride to power several times in the past. But the same scheme is now being watered down by the beneficiaries themselves, both eligible and ineligible, apart from the deep nexus between the dealers and black marketeers. About 40 percent of both eligible and ineligible ration cardholders are actually defeating...

-The Hindu Medicines remain overpriced and unaffordable in India. In a country mired in poverty, medical debt remains the second biggest factor for keeping millions in poverty. The international pharmaceutical industry has found its cash cow in India’s beleaguered consumers. With a minimum wage of Rs.250/day for a government worker, a basic wage worker afflicted with a chronic disease like multi-drug-resistant tuberculosis faces penury. His treatment, with drug combinations, which works out...

-The Times of India NEW DELHI: New medicines for treatment of diabetes, hypertension and pneumonia are set to be cheaper from Diwali. Drug price regulator National Pharmaceutical Pricing Authority (NPPA) has capped prices of as many as 18 new brands of essential medicines, most of which are expected to be launched in the market within a fortnight. The regulator has brought these medicines under price regulation using paragraph 5 of the Drugs...